Sugi Predict

Sugi Predict / Compounds / SCHEMBL4763663

SCHEMBL4763663

SCHEMBL4763663

CCCCCN(C(N)=O)c1ncccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ PAX8 Q06710 2/20 0.42
▸ JAK2 O60674 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.39
▸ TP53 P04637 2/20 0.39
▸ LMNA P02545 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ GPX4 P36969 1/20 0.38
▸ MEN1 O00255 1/20 0.36
▸ NR1I2 O75469 1/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ ADRA2A P08913 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ OPRK1 P41145 1/20 0.36
▸ HTR2B P41595 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27880337 0.79 TRPV1 (0.42) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL3055011 0.76 NPC1 (0.65) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL17511990 0.75 FAAH (0.44) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL4024848 0.75 NPC1 (0.68) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL11344796 0.75 NPC1 (0.68) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL7096422 0.75 NPC1 (0.68) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL10767534 0.75 NPC1 (0.41) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL6424475 0.75 NPC1 (0.68) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL1082836 0.75 NPC1 (0.68) NPC1RAB9APAX8JAK2ALDH1A1
SCHEMBL11344801 0.75 NPC1 (0.68) NPC1RAB9APAX8JAK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2976106-B1 COMBINATION THERAPY COMPRISING A B-RAF INHIBITOR AND A SECOND INHIBITOR ARRAY BIOPHARMA INC (US) 2021-04-14 — — EP disclosed
CN-112641787-A Combination therapy comprising a B-Raf inhibitor and a second inhibitor 诺华股份有限公司 2021-04-13 — — CN disclosed
US-20200246338-A1 COMBINATION THERAPY NOVARTIS AG (CH) 2020-08-06 — — US disclosed
US-10548894-B2 Combination therapy ARRAY BIOPHARMA INC. (US) 2020-02-04 — — US disclosed
US-20180221370-A1 COMBINATION THERAPY ARRAY BIOPHARMA INC. 2018-08-09 — — US disclosed
CN-108348519-A Chlorobenzene-substituted azaaryl compounds 台北医学大学 2018-07-31 — — CN disclosed
EP-3324970-A1 CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS Taipei Medical University (TW) 2018-05-30 — — EP disclosed
US-9913844-B2 Combination therapy NOVARTIS AG (CH) 2018-03-13 — — US disclosed
WO-2017015400-A1 CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS TAIPEI MEDICAL UNIVERSITY (TW) 2017-01-26 — — WO disclosed
US-20160296520-A1 COMBINATION THERAPY NOVARTIS AG (CH) 2016-10-13 — — US disclosed
CN-101336237-B As the pyrimidinyl aryl urea derivatives of FGF inhibitor NOVARTIS AG (CH) 2015-09-30 — — CN disclosed
CN-101336237-B As the pyrimidinyl aryl urea derivatives of FGF inhibitor NOVARTIS AG (CH) 2015-09-30 — — CN disclosed
WO-2014147573-A2 COMBINATION THERAPY NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
US-20130030171-A1 Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors NOVARTIS AG (CH) 2013-01-31 — — US disclosed
US-8293746-B2 Pyrimidinyl aryl urea derivatives being FGF inhibitors NOVARTIS AG (CH) 2012-10-23 — — US disclosed
CN-101336237-A Pyrimidinyl aryl urea derivatives being fgf inhibitors NOVARTIS AG (CH) 2008-12-31 — — CN disclosed
CN-101336237-A Pyrimidinyl aryl urea derivatives being fgf inhibitors NOVARTIS AG (CH) 2008-12-31 — — CN disclosed
US-20080312248-A1 Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors NOVARTIS AG 2008-12-18 — — US disclosed
EP-1976847-A2 PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS Novartis AG (CH) 2008-10-08 — — EP disclosed
WO-2007071752-A2 PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS NOVARTIS AG (CH) 2007-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200246338-A1 COMBINATION THERAPY BRAF, FGFR1, RAF1 NPC1 4016/4885RAB9A 1763/4885PAX8 1540/4885
US-20080312248-A1 Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors FGFR1, FGF1, FGF2 NPC1 2441/4885RAB9A 1936/4885PAX8 2104/4885
US-20160296520-A1 COMBINATION THERAPY BRAF, FGFR1, RAF1 NPC1 3963/4885RAB9A 1754/4885PAX8 1641/4885
US-10548894-B2 Combination therapy BRAF, FGFR1, RAF1 NPC1 3963/4885RAB9A 1754/4885PAX8 1641/4885
US-20180221370-A1 COMBINATION THERAPY BRAF, FGFR1, RAF1 NPC1 3963/4885RAB9A 1754/4885PAX8 1641/4885
US-20130030171-A1 Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors FGFR1, FGF1, FGF2 NPC1 2441/4885RAB9A 1936/4885PAX8 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.